VIA CERTIFIED MAIL

Ian S. Chart
Director of Regulatory Affairs
AMVAC Chemical Corporation
4695 MacArthur Court, Suite 1250
Newport Beach, CA 92660

Dear Mr. Chart:

This letter is to transmit Office of Pesticide Programs' (OPP) preliminary risk human health assessment for the organophosphate (OP) mevinphos. Although there are no active U.S. registrations, we understand that AMVAC Chemical Corporation has foreign registrations, and food commodities treated with mevinphos may be imported into the United States. We are providing you with a 30-day period to identify and comment on errors only. Your comments must be received within 30 days of receipt of this letter. The Agency will review and evaluate your comments on errors upon receipt. On or about December 28, 1999, the preliminary risk assessment, your comments and the Agency's review and discussion of your comments will be placed into OPP's Public Docket. The docket will be opened for public comment for 60 days from the date of publication of a Notice of Data Availability in the *Federal Register*. Additionally, the preliminary risk assessment will be placed on the internet at the same time. This process is part of the Agency's efforts to involve the public in the implementation of the Food Quality Protection Act of 1996 and serves as an interim measure to improve the transparency of the reregistration and tolerance reassessment processes.

During this 30-day comment period, the Agency asks for comments on errors, confidential business information (CBI), and planned data. The Agency will respond only to errors which do not pertain to matters of policy, interpretation, or applicability of data. Errors include, but are not limited to, mathematical, computational, typographic, or other similar errors. In the process of reviewing the Agency's preliminary risk assessment, we ask that you inform us in writing of any claims of CBI contained in this assessment. If we do not receive notification in writing of any such claims within 30 days, the Agency will assume that the document is free of CBI. Also, we request that you inform the Agency of any pertinent, on-going or planned studies, or other sources of information on mevinphos, and your timetable for completing and submitting such data and information to the Agency. This will enable the Agency to plan better for refining the risk assessment and completing mevinphos' tolerance reassessment.

If during this thirty day period, you submit comments other than on errors, you should clearly indicate that they are submitted in advance for the 60-day public comment period. You should provide a brief summary of the comment and refer to an attachment which provides a more in-depth discussion.

In the attachments, you may note that this preliminary human health risk assessment for mevinphos inadvertently refers to the development of a mevinphos Reregistration Eligibility Decision (RED). However, since all mevinphos-containing products registered in the United States have been canceled, there is no associated RED for mevinphos. The risk assessment for mevinphos is being developed in the context of tolerance reassessment.

Please mail your response, any claims of CBI and other information about mevinphos to Joseph Nevola, the Chemical Review Manager (CRM). In addition, provide the CRM your response and any supporting material in both hard copy and electronic form. If you have any questions, please contact him at (703) 308-8037.

Sincerely,

Robert McNally, Chief
Special Review Branch
Special Review and
Reregistration Division

Attachments (7)